We continue working to develop and obtain the Food and Drug Administration (FDA) authorization to market potentially reduced risk tobacco products and provide truthful and accurate communications about them to adult tobacco consumers.

In support of this work we regularly engage with the scientific, public health, and regulatory communities through face-to-face meetings, regulatory filings, publishing in scientific journals and participating at scientific conferences where we present our research. We listen to and welcome feedback on our work.

Reach Out

We are always interested in hearing from other scientists and stakeholders. If you have questions, would like to provide feedback on our work, or learn more about our research and our approach to harm reduction, contact us today.

Paige Magness Photo

Paige Magness

Senior Vice President, Regulatory Affairs

"For decades we have been committed to offering adult smokers better alternatives and ensuring a regulatory framework to determine if those products offer lower risk and how to appropriately communicate about them. We’re fully engaged in the science, policy and regulatory dialogue necessary to innovate and deliver acceptable alternatives adult smokers need and want."

Altria Scientists at the 2020 CORESTA Online Congress Conference - Oct. 12 to Nov. 12

For decades our scientists have been a part of the Cooperation Centre for Scientific Research Relative to Tobacco (CORESTA). This year our scientists participated in the 2020 CORESTA Online Congress through working group meetings and showcasing 7 presentations and 3 posters.

Recent Publication

Estimating the Population Health Impact of Recently Introduced Modified Risk Tobacco Products: A Comparison of Different Approaches.

Recent Publication

A 6-month Systems Toxicology Inhalation Study in ApoE -/- Mice Demonstrates Reduced Cardiovascular Effects of E-vapor Aerosols Compared With Cigarette Smoke.

Recent Publication

Method development and validation of dissolution testing for nicotine release from smokeless tobacco products using flow-through cell apparatus and UPLC-PDA.